Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 6/20 | 0.59 |
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.59 |
| ▸ | PARP1 | P09874 | 2/20 | 0.40 |
| ▸ | EIF4EBP1 | Q13541 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | FABP4 | P15090 | 3/20 | 0.37 |
| ▸ | EIF4E | P06730 | 1/20 | 0.37 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.37 |
| ▸ | MYC | P01106 | 1/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4739410 | 0.86 | XDH (0.53) | XDHSLC22A12PARP1EIF4EBP1FABP4 | |
| SCHEMBL4734197 | 0.84 | XDH (0.47) | XDHSLC22A12PARP1EIF4EBP1FABP4 | |
| SCHEMBL4735319 | 0.83 | XDH (0.48) | XDHSLC22A12PARP1FABP4 | |
| SCHEMBL4734731 | 0.83 | XDH (0.46) | XDHSLC22A12MAP4K4PTGER4MMP2 | |
| SCHEMBL1510051 | 0.82 | XDH (0.44) | XDHSLC22A12PARP1EIF4EBP1FABP4 | |
| SCHEMBL4733776 | 0.82 | PARP1 (0.52) | XDHSLC22A12PARP1FABP4 | |
| SCHEMBL4736983 | 0.82 | XDH (0.44) | XDHSLC22A12PARP1EIF4EBP1FABP4 | |
| SCHEMBL4733740 | 0.82 | MCL1 (0.49) | XDHSLC22A12PARP1FABP4 | |
| SCHEMBL4735090 | 0.80 | XDH (0.43) | XDHSLC22A12PARP1FABP4EIF4E | |
| SCHEMBL4785932 | 0.80 | ACMSD (0.49) | XDHSLC22A12PARP1FABP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207728-A1 | BICYCLIC ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2008-08-28 | — | — | US | claimed |
| WO-2008071455-A1 | BICYCLIC ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-19 | — | — | WO | claimed |
| US-20080207728-A1 | BICYCLIC ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2008-08-28 | — | — | US | disclosed |
| WO-2008071455-A1 | BICYCLIC ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207728-A1 | BICYCLIC ACYLTRYPTOPHANOLS | FSHR, GNRHR, TPH1 | XDH 2848/4885SLC22A12 2654/4885PARP1 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.